Clinical applications of xF

Question 1

Upfront order, stand alone test

Answer 1

• no solid tissue available (ex. Lung/colorectal cancer)
• doctor prefers/is accustomed to liquid biopsy
• doctor prefers shorter TAT (turn around time) of liquid biopsy

Question 2

Concurrent order:

Answer 2

• order with xT to compliment solid tumor analysis, potential to detect additional alterations.

Question 3

Longitudinal testing:

Answer 3

• profile tumor evolution since solid tumor profiling
• Want to monitor how the cancer is acting in the patients body.
• monitoring of treatment response/resistance over time.

Question 4

Conversion testing:

Answer 4

• insufficient tissue for sequencing:
  a) pathology team rejected it
  b) QNS (quantity/quality not sufficient)

Question 5

xF is not intended for use in certain cancers. which are these?

Answer 5

a) early-stage cancers
b) hematologic malignancies (leukemia, lymphomas)
c) tumor types with low ctDNA shed (renal cancers)
d) minimal residual disease

Question 6

xF validation publication. when was it published?

Answer 6

2021, primarily, Tempus authors in partner with a cancer center in Ohio.

Question 7

Sample cohort:

Answer 7

321 samples total

sequenced 310

Question 8

xF can identify additional clinically relevant biomarkers, T or F?

Answer 8

True

Question 9

Tempus xF can detect clinically relevant gene alterations for patients of all ages, cancer types and clinical histories. T or F?

Answer 9

True

Question 10

What genomic variants do we see?

Answer 10

• potentially actionable
• biologically relevant
• no incidental germline
• VAF: median variant allele fraction
• immunotherapy markers (MSI- H only)
• FDA approved therapies (current diagnosis and others)
• Clinical trails a patient has been matched too.

Question 11

benefits of this test:

Answer 11

• testing with xT provides most comprehensive answers.
• does not require procuring tissue
• automatic conversion from xT is an option
• quicker turnaround time

Question 12

when would a Tempus xT order convert to xF?

Answer 12

When the clinician checks the rec on the order form and submits a normal match in the streck tube. Need to get the additional solid tissue sample.

Question 13

why might a clinician choose to order xF instead of xT?

Answer 13

• Longitudinal purposes. Following the progression of the patient’s cancer and tracking progression.
• It’s easier for some cancer’s like lungs because it’s less invasive. Avoiding invasive procedures is the main concern for some doctors.
• Shorter turnaround time. The results will come back quicker.

Question 14

Explain what is meant by using xF longitudinally?

Answer 14

• We are trying to see if the therapy worked. Did they develop resistance to some therapies? We are tracking the evolution of cancer. Doctors can send in as many samples as they want for up to 18 months if the patient is approved for the financial assistance program**

Question 15

Can the patient re-apply after 18 months?

Answer 15

Yes. The patient can.

Question 16

Why is it important to use the streck tube instread of EDTA for the nomrla match when ordering xT?

Answer 16

Allows us to separate the contents via centrifuge. This will break down the plasma, buffy coat, and erythrocytes.

Question 17

We want to get the cell-free DNA out of the plasma, correct?

Answer 17

Yes, that’s the goal.

Question 18

Indications for xF:

Answer 18

Convert, concurrent, longitudinal and stand-alone